PHE News

Precision for Medicine Acquires Precision Health Economics

Extends Leadership in Health Economics and Outcomes Research With a Focus on Evidence Generation in an Era of Precision Medicine.

Precision for Medicine, a specialized services company supporting next-generation approaches to drug development and commercialization, today announced the acquisition of Precision Health Economics (PHE).


Precision Digital Trends Survey: What Payers Want From Pharma Can Vary

Precision Advisors released new findings from its 2015 Digital Trends Study of managed care execs on the types of information Managed Care Org. request and receive from pharma companies.


Precision's MacEwan Discusses Diabetes for NEHI's "On Call" Series

Economist Joanna MacEwan discussed her recent diabetes study and ADA presentation as part of The Network for Excellence in Health Innovation's (NEHI) "On Call" series.


Philipson in Forbes: "Dying to Live"

Tomas Philipson's latest Op-Ed examines end of life care, and why health care is so valuable in the face of death.


Precision's Renick and Blandford in Value Based Cancer Care Magazine

Precision’s Dan Renick and Larry Blandford discuss the implications of the new provider-driven value assessment tools in oncology in the July issue of Value Based Cancer Care magazine.

  • Academic Insights at

    the Speed of Business

  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Medicine, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

  • Academic Insights at

    the Speed of Business